Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Saved in:
| Title: | Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. |
|---|---|
| Authors: | Wang, De-Shen1 (AUTHOR), Ren, Chao1 (AUTHOR), Li, Shan-Shan2 (AUTHOR), Fong, William Pat1 (AUTHOR), Wu, Xiao-Jun3 (AUTHOR), Xiao, Jian2,4 (AUTHOR), Li, Bin-Kui5 (AUTHOR), Zheng, Yun5 (AUTHOR), Ding, Pei-Rong3 (AUTHOR), Chen, Gong3 (AUTHOR), Qiu, Miao-Zhen1 (AUTHOR), Wang, Zhi-Qiang1 (AUTHOR), Wang, Feng-Hua1 (AUTHOR), Luo, Hui-Yan1 (AUTHOR), Wang, Feng1 (AUTHOR), Wang, Xiao-Zhong6 (AUTHOR), Wang, Ling-Yun7 (AUTHOR), Xie, De-Jin6 (AUTHOR), Chen, Tao7 (AUTHOR), Li, Li-Ren3 (AUTHOR) |
| Source: | PLoS Medicine. 5/10/2024, Vol. 21 Issue 5, p1-18. 18p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 15491277 |
|---|---|
| DOI: | 10.1371/journal.pmed.1004389 |
